Journal of Infection and Public Health, 2023 Background: Paxlovid is an oral drug composed of nirmatrelvir and ritonavir that has been demonstrated to be effective in decreasing the risk of severe coronavirus disease 2019 (COVID-19).
Chih-Wei Lin +5 more
doaj +1 more source
The effectiveness of Paxlovid treatment in long-term care facilities in South Korea during the outbreak of the Omicron variant of SARS-CoV-2 [PDF]
Osong Public Health and Research Perspectives, 2022 Objectives On November 5, 2021, Pfizer Inc. announced Paxlovid (nirmatrelvir+ritonavir) as a treatment method that could reduce the risk of hospitalization or death for patients with confirmed coronavirus disease 2019 (COVID-19). Methods From February 6,
Hanul Park +8 more
doaj +1 more source
Severe COVID-19 following Rituximab and Nirmatrelvir/ritonavir treatment in a patient with MCTD, Case Report [PDF]
, 2023 This is an article about how the use of medications such as nirmatrelvir/ritonavir can cause rebound COVID-19 and how the use of Rituximab, a biologic agent, can prolong the duration and increase severity of symptoms of COVID-19 in patients with pre ...
Baig, Rohail A +5 more
core +2 more sources
Journal of Translational Medicine, 2022 Background The COVID-19 pandemic has become a huge threat to human health, infecting millions of people worldwide and causing enormous economic losses.
Keyu Kong +10 more
doaj +1 more source
A Lung-Immune Dual-Humanized Mouse Using Cryopreserved Tissue Enables Infection and Immune Profiling of Human Common Cold Coronaviruses. [PDF]
Adv Sci (Weinh)Cryopreserved lung‐humanized mice overcome the dependency to fresh tissues and permit head‐to‐head profiling of all four human common cold coronaviruses versus SARS‐CoV‐2 infection; the model validates Paxlovid efficacy against HKU1 and, when coupled with human immune‐system engraftment, enables interrogation of lung‐resident human immunity and HKU1 ...
Cheng C +9 more
europepmc +2 more sources
The Public Health Impact of Paxlovid COVID-19 Treatment in the United States [PDF]
, 2023 The antiviral drug Paxlovid has been shown to rapidly reduce viral load. Coupled with vaccination, timely administration of safe and effective antivirals could provide a path towards managing COVID-19 without restrictive non-pharmaceutical measures. Here,
Bai, Yuan +9 more
core +2 more sources
Posterior Reversible Encephalopathy Syndrome in an Older Patient in the COVID-19 and Paxlovid Era
Annals of Internal Medicine: Clinical Cases, 2023 Nirmatrelvir/ritonavir (Paxlovid) has been prescribed increasingly for treatment of COVID-19. Due to ritonavir's inhibition of CYP3A4, there are many medication interactions to consider.
Katharine Rosiene +4 more
doaj +1 more source
Safety and Efficacy of Paxlovid in COVID-19 Treatment: A Rapid Review
Health Technology Assessment in Action, 2022 Context: In the first stage of viral replication, COVID-19 may cause a remarkable inflammatory response in patients. Paxlovid is an oral antivirus medicine that functions through the inhibition of one of the essential enzymes to viral replication, called
Mohamad Reza Mobinizadeh +8 more
doaj +1 more source
Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY [PDF]
, 2023 Objective: To ascertain patient eligibility status and describe coverage of antiviral drugs and neutralising monoclonal antibodies (nMAB) as treatment for covid-19 in community settings in England.
Andrews, Colm D +41 more
core +2 more sources
Paxlovid-Induced Symptomatic Bradycardia and Syncope
Cureus, 2023 Paxlovid (nirmatrelvir/ritonavir) is a game changer in the fight against COVID-19 due to its ease of administration and significant benefits of reducing progression to severe COVID-19, hospitalization, and death. Cardiac adverse events such as bradycardia and syncope are not known with this medication.
Ganipisetti, Venu M +2 more
openaire +2 more sources